Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 27 citing articles:

MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
Martin Reck, Ernest Nadal, Nicolas Girard, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 6, pp. 587-593.e3
Closed Access | Times Cited: 12
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access | Times Cited: 1
Neoadjuvant or Perioperative Approach in Lung Cancer
Marina Chiara Garassino, Valter Torri
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1816-1818
Closed Access | Times Cited: 7
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
Ze-Rui Zhao, Shiliang Liu, Ting Zhou, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 12, pp. 988-996
Closed Access | Times Cited: 6
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli, A. Nuccio, Alessandro Di Federico, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 4
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Artificial Intelligence-Based Algorithm for Pathological Response Assessment to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Multi-Center Derived Platform Can Shrink a Mountainous Task into a Molehill
Fujin Ye, Mian Chen, Chao Wang, et al.
(2025)
Closed Access
Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist’s Perspective
Konrad Steinestel, Annette Arndt
Diagnostics (2025) Vol. 15, Iss. 5, pp. 631-631
Open Access
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010928-e010928
Open Access
Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis
Y. Liu, Jianlin Long, Huan Deng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
Carmine Valenza, Erick Figueiredo Saldanha, Yi Gong, et al.
Annals of Oncology (2025)
Closed Access
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
Chaoqi Zhang, Peng Wu, Dongyu Li, et al.
Med (2025), pp. 100669-100669
Closed Access
The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy
Yuyan Xie, Zhihao Shi, Tong Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A narrative review on perioperative systemic therapy in non-small cell lung cancer
Robert Hsu, Zhaohui Arter, Darin Poei, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 4, pp. 931-954
Open Access | Times Cited: 3
Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy
Ze-Rui Zhao, Wanpu Yan, Xiangyang Yu, et al.
Journal of Thoracic and Cardiovascular Surgery (2024)
Closed Access | Times Cited: 2
Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations

ESMO Open (2024) Vol. 9, Iss. 8, pp. 103649-103649
Open Access | Times Cited: 1
Perioperative immunotherapy for nonsmall cell lung cancer
Jingya Huang, Wenyuan Li, Hui Guo
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
In the Era of Precision Medicine, Is Invasive Mediastinal Restaging Really Not Required Before Lung Resection?
Sergi Call, Nina Reig-Oussedik, Bruno García‐Cabo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. e96-e97
Closed Access | Times Cited: 1
Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
Hyein Jeon, Rajvi Gor, Angelica D’Aiello, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC
Filippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, et al.
Lung Cancer (2024) Vol. 194, pp. 107900-107900
Closed Access
A Response Letter by Cameron et al
Robert B. Cameron, Jacobi Hines, Valter Torri, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. e26-e28
Closed Access
The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC
Ben Ponvilawan, Janakiraman Subramanian, Dhruv Bansal
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. e24-e26
Closed Access
Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer
Rafał Dziadziuszko, Bartłomiej Tomasik
The Lancet Respiratory Medicine (2024)
Closed Access
Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable NSCLC”
Da Jiang, Fei Yang, Huiwei Deng
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. e79-e80
Closed Access
Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”
Robert B. Cameron, Jacobi Hines, Valter Torri, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. e80-e81
Closed Access
Page 1 - Next Page

Scroll to top